Stock Financial Ratios and Split History

RARX / Ra Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)209.54
Enterprise Value ($M)139.16
Book Value ($M)69.18
Book Value / Share2.14
Price / Book3.03
NCAV ($M)61.86
NCAV / Share1.92
Price / NCAV3.36
Income Statement (mra) ($M)
Net Income-54.44
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio8.46
Current Ratio8.46
Share Statistics
Preferred Stock Shares Outstanding0
Common Shares Outstanding32,286,684
Common Stock Shares Outstanding22,626,000
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.79
Return on Assets (ROA)-0.43
Return on Equity (ROE)-0.46
Identifiers and Descriptors
Central Index Key (CIK)1481512
Industry Groups

Split History

Stock splits are used by Ra Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers -

Related News Stories

Alexion Passes Phase 3 Study, Looks To Expand On Rare Blood Disease Indication

12h seekingalpha
Alexion Pharmaceuticals achieves co-primary endpoints in phase 3 study treating patients with a rare blood disease. (58-0)

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

2018-03-14 reuters

Alexion Ups Its Game With ALXN1210 SC

2018-02-20 seekingalpha
Alexion Pharmaceuticals (ALXN) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, which is an effective mechanism of action in treating the rare diseases paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). (156-2)

Ra Pharmaceuticals: A Full Investment Analysis

2018-02-19 seekingalpha
Today we look at Ra Pharmaceuticals.  This company just completed a secondary offering this week where two directors bought just over $3 million in new shares. (18-4)

Your Daily Pharma Scoop: Shire Looks Attractive, Omeros Data, Axovant Restructuring

2018-02-15 seekingalpha
Today we will discuss Shire Plc (SHPG), which is continuing with its bad run. Year to date, SHPG shares have fallen nearly 14%. Of course, the sell-off this year can be attributed to the bearish sentiment in general in the market. But Shire also had a disappointing 2017 even as the NBI posted gains of more than 21%. (210-2)

CUSIP: 74933V108